Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2‐positive breast cancerNoor Mazin Abdulkareem, Meghana V. Trivedi, Hee‐Yong Kim et al.|British Journal of Pharmacology|2025Cited by 6
Abstract 5166: A multiplexed immunofluorescence assay to assess Rb and phospho-Rb as predictive biomarkers for CDK4/6 inhibitors in HR+/HER2- breast cancerMantasha Tabassum, Meghana V. Trivedi, Shivaani Suresh Kanna et al.|Cancer Research|2024Cited by 0
Abstract 5250: Method development and workflow optimization of a CTC-based biomarker assay to predict response to CDK4/6 inhibitors in HR+/HER2- breast cancerMantasha Tabassum, Meghana V. Trivedi, Shivaani Suresh Kanna et al.|Cancer Research|2026Cited by 0
Abstract 457: Nebivolol triggers apoptosis, ferroptosis and necroptosis in triple-negative breast cancer.Wangjia Cao, Meghana V. Trivedi, Anh Tuan Vuong et al.|Cancer Research|2026Cited by 0
Abstract 4462: Nebivolol inhibits cell growth, inhibits autophagic flux, and enhances growth inhibition in combination with bicalutamide in prostate cancer cells.Swarnil Mandal, Meghana V. Trivedi, Chia‐Ling Wu et al.|Cancer Research|2026Cited by 0